LV13248B - A food supplement comprising polyphenols and use in treatment of cancer - Google Patents
A food supplement comprising polyphenols and use in treatment of cancer Download PDFInfo
- Publication number
- LV13248B LV13248B LVP-04-93A LV040093A LV13248B LV 13248 B LV13248 B LV 13248B LV 040093 A LV040093 A LV 040093A LV 13248 B LV13248 B LV 13248B
- Authority
- LV
- Latvia
- Prior art keywords
- cancer
- ascorbic acid
- proline
- lysine
- ascorbate
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 122
- 201000011510 cancer Diseases 0.000 title claims abstract description 104
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 68
- 238000011282 treatment Methods 0.000 title claims abstract description 38
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims description 43
- 235000015872 dietary supplement Nutrition 0.000 title claims 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 210
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 106
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 106
- 229960002429 proline Drugs 0.000 claims abstract description 98
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 94
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 91
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 67
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 67
- 229940030275 epigallocatechin gallate Drugs 0.000 claims abstract description 66
- 239000000203 mixture Substances 0.000 claims abstract description 54
- -1 polyphenol compound Chemical class 0.000 claims abstract description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 46
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000005487 catechin Nutrition 0.000 claims abstract description 24
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims abstract description 24
- 229930182821 L-proline Natural products 0.000 claims abstract description 14
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 13
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims abstract description 13
- 229950001002 cianidanol Drugs 0.000 claims abstract description 13
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims abstract description 12
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000012734 epicatechin Nutrition 0.000 claims abstract description 12
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims abstract description 11
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims abstract description 11
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims abstract description 11
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims abstract description 11
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims abstract description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-Lysine Natural products NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 91
- 239000004472 Lysine Substances 0.000 claims description 87
- 229960003646 lysine Drugs 0.000 claims description 87
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 84
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 81
- 235000018977 lysine Nutrition 0.000 claims description 81
- 235000013930 proline Nutrition 0.000 claims description 77
- 230000000694 effects Effects 0.000 claims description 45
- 201000001441 melanoma Diseases 0.000 claims description 35
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 30
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 30
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 30
- 229960004308 acetylcysteine Drugs 0.000 claims description 30
- 239000010949 copper Substances 0.000 claims description 30
- 229910052802 copper Inorganic materials 0.000 claims description 30
- 239000011669 selenium Substances 0.000 claims description 30
- 229910052711 selenium Inorganic materials 0.000 claims description 30
- 230000035755 proliferation Effects 0.000 claims description 29
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 28
- 229940047036 calcium ascorbate Drugs 0.000 claims description 28
- 239000011692 calcium ascorbate Substances 0.000 claims description 28
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 28
- 229940074358 magnesium ascorbate Drugs 0.000 claims description 28
- 208000029742 colonic neoplasm Diseases 0.000 claims description 26
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 claims description 26
- 208000026310 Breast neoplasm Diseases 0.000 claims description 25
- 206010009944 Colon cancer Diseases 0.000 claims description 25
- 239000004475 Arginine Substances 0.000 claims description 24
- 235000009697 arginine Nutrition 0.000 claims description 24
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 24
- 206010006187 Breast cancer Diseases 0.000 claims description 23
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 22
- 239000011572 manganese Substances 0.000 claims description 22
- 229910052748 manganese Inorganic materials 0.000 claims description 22
- 235000011649 selenium Nutrition 0.000 claims description 22
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 21
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 20
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 18
- 239000011575 calcium Substances 0.000 claims description 18
- 229910052749 magnesium Inorganic materials 0.000 claims description 18
- 239000011777 magnesium Substances 0.000 claims description 18
- 206010027476 Metastases Diseases 0.000 claims description 16
- 230000009401 metastasis Effects 0.000 claims description 16
- 235000001465 calcium Nutrition 0.000 claims description 14
- 235000001055 magnesium Nutrition 0.000 claims description 14
- 229940072107 ascorbate Drugs 0.000 claims description 12
- 230000000903 blocking effect Effects 0.000 claims description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 9
- 229930064664 L-arginine Natural products 0.000 claims description 9
- 235000014852 L-arginine Nutrition 0.000 claims description 9
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical group CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 7
- 235000019766 L-Lysine Nutrition 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- UAGFTQCWTTYZKO-WCCKRBBISA-N (2s)-pyrrolidine-2-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H]1CCCN1 UAGFTQCWTTYZKO-WCCKRBBISA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 150000003147 proline derivatives Chemical class 0.000 claims description 4
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 3
- 229960005337 lysine hydrochloride Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 229940070404 citrus bioflavonoids Drugs 0.000 claims description 2
- 235000020939 nutritional additive Nutrition 0.000 claims 3
- 150000000996 L-ascorbic acids Chemical class 0.000 claims 2
- 229920006389 polyphenyl polymer Polymers 0.000 claims 2
- 229960003121 arginine Drugs 0.000 claims 1
- 229940108928 copper Drugs 0.000 claims 1
- QUQFTIVBFKLPCL-UHFFFAOYSA-L copper;2-amino-3-[(2-amino-2-carboxylatoethyl)disulfanyl]propanoate Chemical compound [Cu+2].[O-]C(=O)C(N)CSSCC(N)C([O-])=O QUQFTIVBFKLPCL-UHFFFAOYSA-L 0.000 claims 1
- 229940091258 selenium supplement Drugs 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 abstract description 69
- 102100032912 CD44 antigen Human genes 0.000 abstract description 39
- 108010069264 keratinocyte CD44 Proteins 0.000 abstract description 39
- 238000000034 method Methods 0.000 abstract description 9
- 230000009545 invasion Effects 0.000 description 44
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 30
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 30
- 108010082117 matrigel Proteins 0.000 description 29
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 23
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 23
- 230000002401 inhibitory effect Effects 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- 150000001765 catechin Chemical class 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 244000269722 Thea sinensis Species 0.000 description 11
- 235000009569 green tea Nutrition 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000009469 supplementation Effects 0.000 description 11
- 150000000994 L-ascorbates Chemical class 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 9
- 108010088842 Fibrinolysin Proteins 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 210000002744 extracellular matrix Anatomy 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 229940012957 plasmin Drugs 0.000 description 9
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 8
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000005012 migration Effects 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 238000007805 zymography Methods 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 210000001612 chondrocyte Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000013382 Gelatinases Human genes 0.000 description 5
- 108010026132 Gelatinases Proteins 0.000 description 5
- 102000013566 Plasminogen Human genes 0.000 description 5
- 108010051456 Plasminogen Proteins 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 102100030416 Stromelysin-1 Human genes 0.000 description 3
- 101710108790 Stromelysin-1 Proteins 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000002001 anti-metastasis Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940094952 green tea extract Drugs 0.000 description 3
- 235000020688 green tea extract Nutrition 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 102100030411 Neutrophil collagenase Human genes 0.000 description 2
- 101710118230 Neutrophil collagenase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000001740 anti-invasion Effects 0.000 description 2
- 229940086761 arginine 500 mg Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 150000002206 flavan-3-ols Chemical class 0.000 description 2
- 235000011987 flavanols Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229930013783 (-)-epicatechin Natural products 0.000 description 1
- 235000007355 (-)-epicatechin Nutrition 0.000 description 1
- YLCSLYZPLGQZJS-VDQHJUMDSA-N (2r)-2-acetamido-3-sulfanylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(=O)N[C@@H](CS)C(O)=O.NCCCC[C@H](N)C(O)=O YLCSLYZPLGQZJS-VDQHJUMDSA-N 0.000 description 1
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 description 1
- PBZMVAYHJDFHIR-UHFFFAOYSA-N 2-phenyl-3,4-dihydrochromene-2,3-diol Chemical class OC1CC2=CC=CC=C2OC1(O)C1=CC=CC=C1 PBZMVAYHJDFHIR-UHFFFAOYSA-N 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000015422 Rumex crispus ssp. crispus Nutrition 0.000 description 1
- 235000015426 Rumex crispus ssp. fauriei Nutrition 0.000 description 1
- 244000207667 Rumex vesicarius Species 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- XBMHEPJKDOHTFC-UHFFFAOYSA-N [Se].[Mn].[Cu] Chemical compound [Se].[Mn].[Cu] XBMHEPJKDOHTFC-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940086708 ascorbic acid 250 mg Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- VVYPIVJZLVJPGU-UHFFFAOYSA-L copper;2-aminoacetate Chemical compound [Cu+2].NCC([O-])=O.NCC([O-])=O VVYPIVJZLVJPGU-UHFFFAOYSA-L 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 229940097206 manganese citrate Drugs 0.000 description 1
- 235000014872 manganese citrate Nutrition 0.000 description 1
- 239000011564 manganese citrate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003342 selenium Chemical class 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Claims (20)
- LV 13248 PRETENZIJAS 1. Uztura piedevas, izmantojamas vēža ārstēšanai, kas satur a) askorbīnskābes savienojumu; b) L-lizīna savienojumu; c) L-prolīna savienojumu; un d) vismaz vienu polifenola savienojumu, kas izvēlēts no grupas, kas sastāv no epigallokatehīna gallāta, epikatehīna gallāta, epigallokatehīna, epikatehīna un katehīna, kurā savienojumi a)- c) pastiprina polifenla savienojuma aktivitāti vēža proliferācijas un metastāzes bloķēšanā.
- 2. Uztura piedevas saskaņā ar 1. punktu, kurās askorbīnskābes savienojums ir izvēlēts no grupas, kas sastāv no askorbīnskābes, farmaceitiski pieņemamiem askorbīnskābes sāļiem, askorbīnskābes esteriem un/vai to maisījumiem.
- 3. Uztura piedevas saskaņā ar 2. punktu, kurās farmaceitiski pieņemamais askorbīnskābes sāls ir kalcija askorbāts vai magnija askorbāts.
- 4. Uztura piedevas saskaņā ar 2. punktu, kurās askorbāta esteris ir askorbīnskābes palmitāts.
- 5. Uztura piedevas saskaņā ar 1. punktu, kurās lizīna savienojums ir izvēlēts no grupas, kas sastāv no lizīna hidrohlorīda un lizīnam farmaceitiski pieņemamiem lizīna sāļiem.
- 6. Uztura piedevas saskaņā ar 1. punktu, kurās prolīna savienojums ir izvēlēts no grupas, kas sastāv no prolīna hidrohlorīda un prolīnam farmaceitiski pieņemamiem prolīna sāļiem.
- 7. Uztura piedevas saskaņā ar 1. punktu, kas papildus satur mikroelementu, kas izvēlēts no grupas, kas sastāv no selēna, vara, mangāna, kalcija un magnija.
- 8. Uztura piedevas saskaņā ar 1. punktu, kas papildus satur aminoskābi.
- 9. Uztura piedevas saskaņā ar 8. punktu, kurās aminoskābe ir arginīns.
- 10. Uztura piedevas saskaņā ar vienu no 1.-9. punktiem, kas papildus satur d) N-acetilcisteīnu.
- 11. Uztura piedevas saskaņā ar 10. punktu, kurās savienojumi a) līdz d) pastiprina polifenila savienojuma aktivitāti vēža proliferācijas un metastāzes bloķēšanā. 2
- 12. Uztura piedevas, izmantojamas vēža ārstēšanai, kas satur: askorblnskābi, kalcija askorbātu, magnija askorbātu, askorbilpalmitātu, polifenolus, N-acetil-cisteīnu, lizīnu, prolīnu, arginīnu, selēnu, varu un mangānu. . Uztura piedevas saskaņā ar 12. punktu, kurās kompozīcija satur: a) 250 mg askorbīnskābes, 250 mg kalcija askorbāta, 250 mg magnija askorbāta, 250 mg askorbila palmitāta, 1000 mg polifenolu, 200 mg N-acetilcistelna, 1000 mg lizīna, 750 mg prolīna, 500mg arginīna, 30 pg selēna, 2 mg vara un 1 mg mangāna; b) 25 mg askorbīnskābes, 25 mg kalcija askorbāta, 25mg magnija askorbāta, 25 mg askorbila palmitāta, 200 mg polifenolu, 10 mg N-acetilcisteīna, 50 mg lizīna, 25 mg prolīna, 50 mg arginīna, 1 pg selēna, 20 pg vara un 50 pg mangāna; c) 5000 mg askorbīnskābes, 5000 mg kalcija askorbāta, 5000 mg magnija askorbāta, 5000 mg askorbila palmitāta, 5000 mg polifenolu, 1500 mg N-acetilcisteīna, 5000 mg lizīna, 3000 mg prolīna, 3000 mg arginīna, 200 pg selēna, 9 mg vara un 10 mg mangāna; d) 250 mg askorbīnskābes, 250 mg kalcija askorbāta, 250 mg magnija askorbāta, 250 mg askorbila palmitāta, 1000 mg polifenolu, 200 mg N-acetilcisteīna, 1000 mg lizīna, 750 mg prolīna, 500 mg arginīna, 100 pg selēna, 2 mg vara, 1 mg mangāna, 500 mg kalcija un 400 mg magnija; vai e) 250 mg askorbīnskābes, 250 mg kalcija askorbāta, 250 mg magnija askorbāta, 250 mg askorbila palmitāta, 1000 mg polifenolu, 200 mg N-acetilcisteīna, 1000 mg lizīna, 750 mg prolīna, 500 mg arginīna, 100 pg selēna, 2 mg vara, 1 mg mangāna, 500 mg kalcija, 400 mg magnija un 200 citrusbioflavonoīdu.
- 14. Uztura piedevas, izmantojamas vēža ārstēšanai, kas satur: L-lizīnu, L-prolīnu, L-arginīnu, askorbīnskābi, kalciju, magniju, polifenolus, N-acetilcisteīnu, selēnu, varu un mangānu.
- 15. Uztura piedevas saskaņā ar 14. punktu, kurā kompozīcija satur 1000 mg L-lizīna, 750 mg L-prolīna, 500 mg L-arginīna, 710 mg askorbīnskābes, 22 mg kalcija, 50 mg magnija, lOOOmg polifenolu, 200mg N-acetilcisteīna, 30 pg selēna, 2 mg vara un 1 mg mangāna. 3 3LV 13248
- 16. Uztura piedevas saskaņā ar 15. punktu, kurās askorbīnskābe ir izvēlēta no grupas, kas sastāv no askorbīnskābes, kalcija askorbāta, magnija askorbāta un askorbilpalmitāta.
- 17. Uztura piedevas saskaņā ar 15. punktu, kurās polifenols ir izvēlēts no grupas, kas sastāv no epigallokatehīna gallāta, epikatehīna gallāta, epigallokatehīna, epikatehīna, katehīna un citiem farmaceitiski pieņemamiem polifenola sāļiem un/ vai to maisījumiem.
- 18. Uztura piedevu, kas aprakstītas vienā no 1. -16. punktiem, pielietojums vēža ārstēšanai paredzētas farmaceitiskas kompozīcijas pagatavošanai.
- 19. Pielietojums saskaņā ar 18. punktu, kurā vēzis ir izvēlēts no grupas, kas sastāv no melanomas vēža, krūts dziedzera vēža, resnās zarnas vēža, plaušu vēža un smadzeņu vēža.
- 20. Uztura piedevu, kas aprakstītas vienā no 1. -16. punktiem, pielietojums iekaisuma slimības ārstēšanai paredzētas farmaceitiskas kompozīcijas pagatavošanai.
- 21. Pielietojums saskaņā ar 20. punktu, kurā iekaisuma slimība ir osteoartrīts.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34814302P | 2002-01-11 | 2002-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LV13248B true LV13248B (en) | 2005-06-20 |
Family
ID=23366808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-04-93A LV13248B (en) | 2002-01-11 | 2004-09-09 | A food supplement comprising polyphenols and use in treatment of cancer |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7041699B2 (lv) |
| EP (1) | EP1465614B1 (lv) |
| JP (1) | JP2005519055A (lv) |
| KR (1) | KR20040073559A (lv) |
| CN (1) | CN100377706C (lv) |
| AT (1) | ATE382343T1 (lv) |
| AU (1) | AU2003235762B2 (lv) |
| BR (1) | BR0302672A (lv) |
| CA (1) | CA2471932A1 (lv) |
| DE (1) | DE60318387T2 (lv) |
| EE (1) | EE200400032A (lv) |
| ES (1) | ES2298519T3 (lv) |
| HK (1) | HK1086489A1 (lv) |
| HR (1) | HRP20040704A2 (lv) |
| HU (1) | HUP0500498A3 (lv) |
| IL (1) | IL162646A0 (lv) |
| LT (1) | LT5240B (lv) |
| LV (1) | LV13248B (lv) |
| MX (1) | MXPA04006717A (lv) |
| NO (1) | NO20033950L (lv) |
| NZ (1) | NZ533737A (lv) |
| PL (1) | PL215159B1 (lv) |
| RU (1) | RU2301666C2 (lv) |
| UA (1) | UA80692C2 (lv) |
| WO (1) | WO2003057201A2 (lv) |
| YU (1) | YU75003A (lv) |
| ZA (1) | ZA200405075B (lv) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034310B2 (en) * | 2002-02-21 | 2015-05-19 | Stephen B. Cantrell | Interferon-statin combination cancer therapy |
| US7115283B2 (en) * | 2003-05-06 | 2006-10-03 | Access Business Group International Llc | Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals |
| US20040253319A1 (en) * | 2003-06-11 | 2004-12-16 | Shrirang Netke | Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy |
| JP2008509877A (ja) * | 2003-09-05 | 2008-04-03 | ラート・マティアス | 通常、ビタミンｃ、マグネシウム、緑茶抽出物を含む心血管系疾患を抑制するための医薬調合物 |
| US8377904B2 (en) * | 2004-02-09 | 2013-02-19 | Hill's Pet Nutrition, Inc. | Composition and method for use in cartilage affecting conditions |
| US20050176674A1 (en) * | 2004-02-09 | 2005-08-11 | Friesen Kim G. | Composition and method for use in cartilage affecting conditions |
| KR100601080B1 (ko) * | 2004-08-26 | 2006-07-19 | 가톨릭대학교 산학협력단 | (-)-에피갈로카테킨 갈레이트를 유효성분으로 하는류마티스성 관절염 치료제 |
| EP2502649A1 (en) | 2005-02-03 | 2012-09-26 | TopoTarget UK Limited | Combination therapy using HDAC inhibitors and erlotinib for treating cancer |
| BRPI0520227A2 (pt) * | 2005-04-11 | 2009-04-22 | Matthias Rath | uso de uma composiÇço nutriente para o tratamento de sarcoma e cÂncer de pràstata |
| WO2006108430A1 (en) | 2005-04-11 | 2006-10-19 | Matthias Rath | Nutrient composition comprising green tea polyphenols for treating osteosarcoma |
| KR101329437B1 (ko) | 2005-05-13 | 2013-11-14 | 토포타겟 유케이 리미티드 | Ｈｄａｃ 억제제의 약학 제형 |
| EP1924257A4 (en) * | 2005-07-26 | 2012-08-08 | Mitsui Norin Kk | STABILIZED 3-HYDROXYFLAVAN COMPOSITIONS AND METHOD THEREFOR |
| WO2007033356A2 (en) * | 2005-09-14 | 2007-03-22 | Mitsui Norin Co., Ltd | Compositions and methods for green tea catechins for modification of detoxification enzymes |
| JP5377968B2 (ja) * | 2005-11-10 | 2013-12-25 | トポターゲット ユーケー リミテッド | 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤 |
| US20070212426A1 (en) * | 2006-03-10 | 2007-09-13 | Matthias Rath | Composition and method of retarding viral activity and reducing viral replication |
| CA2689717C (en) * | 2006-06-16 | 2016-10-18 | Summa Health System | Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone |
| GB0615781D0 (en) * | 2006-08-09 | 2006-09-20 | Coressence Ltd | Prebiotic composition |
| US20080114054A1 (en) * | 2006-11-14 | 2008-05-15 | Rath Microbes | Compositions and methods for reducing antimicrobial resistance of microbes |
| US8617544B2 (en) * | 2007-05-01 | 2013-12-31 | Richard L. Kozlenko | Compositions and methods for controlling lipid metabolism |
| GB0710536D0 (en) * | 2007-06-01 | 2007-07-11 | Veritron Ltd | Plant extract and its therapeutic use |
| CN101868446A (zh) * | 2007-09-25 | 2010-10-20 | 托波塔吉特英国有限公司 | 某些异羟肟酸化合物的合成方法 |
| GB0725077D0 (en) * | 2007-12-21 | 2008-01-30 | Univ Murcia | Antifolate com[ounds for the treatment of melanoma |
| MX2010009642A (es) * | 2008-03-07 | 2010-09-22 | Topotarget As | Metodos de tratamiento utilizando infusion continua prolongada de belinostat. |
| RU2395281C2 (ru) * | 2008-09-04 | 2010-07-27 | Всеволод Иванович Киселев | Фармацевтическая композиция для лечения диспластических процессов шейки матки |
| US9034834B2 (en) | 2008-11-04 | 2015-05-19 | Vymedic, Llc | Antiviral supplement formulations |
| US8677463B2 (en) * | 2008-12-05 | 2014-03-18 | At&T Intellectual Property I, Lp | System and method for managing multiple sub accounts within a subcriber main account in a data distribution system |
| JP2009143928A (ja) * | 2008-12-26 | 2009-07-02 | Kyushu Univ | ガロイルカテキン類の抗酸化活性の促進方法 |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| CN105816498A (zh) | 2009-04-27 | 2016-08-03 | 玫琳凯有限公司 | 植物性抗痤疮制剂 |
| IT1397522B1 (it) * | 2009-12-21 | 2013-01-16 | Solartium Entpr Ltd | Uso di una combinazione per il trattamento dell'osteoartrosi |
| GB201015784D0 (en) | 2010-09-20 | 2010-10-27 | Bionature E A Ltd | Anti-cancer compounds |
| KR102245069B1 (ko) | 2011-12-19 | 2021-04-26 | 마리 케이 인코포레이티드 | 피부톤 향상을 위한 식물 추출물의 조합물 |
| RU2522547C1 (ru) * | 2012-11-12 | 2014-07-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | Фармакологическая геропротекторная композиция и способ ее получения |
| US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| US20160279043A1 (en) * | 2013-03-18 | 2016-09-29 | Dentalmed Pharm Holding Ltd. | Combinations of n-acetyl cysteine derivatives and cranberry polyphenols in compositions and methods for preventing and treating periodontal diseases and peri-implatitis |
| BE1023772B9 (fr) * | 2013-05-17 | 2017-08-02 | Valore | Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer |
| GB2520794A (en) * | 2013-07-26 | 2015-06-03 | Tata Memorial Ct | Plant poly-phenol and copper (II) mediated degradation of DNA and RNA |
| IN2013MU01528A (lv) * | 2013-07-26 | 2015-06-26 | Tata Memorial Ct | |
| KR102323049B1 (ko) | 2014-03-10 | 2021-11-05 | 마리 케이 인코포레이티드 | 피부 라이트닝 조성물 |
| BE1022579A9 (fr) * | 2014-11-10 | 2016-10-06 | Valore | Composition antimétastatique comprenant au moins un composé de type flavanol |
| CN105061533B (zh) * | 2015-09-18 | 2018-02-09 | 福州大学 | 六甲氧基二氢黄酮‑鼠李糖基‑鼠李糖苷及其应用 |
| CN106138036A (zh) * | 2016-04-29 | 2016-11-23 | 陈西敬 | 抗坏血酸棕榈酸酯在制备抗肿瘤药物中的应用 |
| CA3038327C (en) * | 2016-10-03 | 2024-03-12 | Houn Simon Hsia | Compositions and methods for enhancing cancer radiotherapy |
| US12029765B2 (en) | 2017-06-13 | 2024-07-09 | Houn Simon Hsia | Compositions and methods for treating cancer |
| US10905725B2 (en) | 2017-06-13 | 2021-02-02 | Houn Simon Hsia | Compositions and methods for enhancing cancer chemotherapy |
| KR20200078467A (ko) | 2017-06-13 | 2020-07-01 | 호운 사이먼 샤 | 암 방사선요법을 향상시키기 위한 조성물 및 방법 |
| CN111529709A (zh) * | 2020-06-03 | 2020-08-14 | 北京易思腾翻译服务有限公司 | 一种可用于体重控制且可逆转动脉粥样硬化的组合物 |
| WO2022124386A1 (en) * | 2020-12-07 | 2022-06-16 | L' Oreal | Composition comprising ascorbic acid and cyclic amino acid |
| IT202200010592A1 (it) * | 2022-05-23 | 2023-11-23 | Neilos S R L | “Composizione nutraceutica o farmaceutica per l’infertilità maschile” |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4243363A1 (de) * | 1992-12-21 | 1994-06-23 | Ulrich Dr Med Kuebler | Behandlungsverfahren für Hauttrockenheit |
| US5962517A (en) * | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
| US5817695A (en) * | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| EP0938897A1 (en) * | 1997-12-26 | 1999-09-01 | Japanese Foundation For Cancer Research | Telomerase inhibitor |
| AT407821B (de) * | 1998-03-24 | 2001-06-25 | Franz Dr Stueckler | Mittel auf der basis von naturstoffen |
| WO2000057875A1 (en) * | 1999-03-30 | 2000-10-05 | Purdue Research Foundation | Compositions containing tea catechins as cancer specific proliferation inhibitors |
| EP1200075A4 (en) | 1999-06-15 | 2003-05-02 | Nutri Logics Inc | FOOD FORMULATIONS FOR THE BOWING AND TREATMENT OF DISEASES AND SCREENING PROCEDURES OF THE COMPONENTS |
| US6299925B1 (en) * | 1999-06-29 | 2001-10-09 | Xel Herbaceuticals, Inc. | Effervescent green tea extract formulation |
| US6448030B1 (en) * | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| ATE327747T1 (de) * | 2000-10-09 | 2006-06-15 | Matthias Dr Med Rath | Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses |
| WO2007076492A2 (en) | 2005-12-28 | 2007-07-05 | Sandisk Corporation | Methods and systems for writing non-volatile memories for increased endurance |
-
2003
- 2003-01-13 RU RU2004124384/15A patent/RU2301666C2/ru active IP Right Revival
- 2003-01-13 CA CA002471932A patent/CA2471932A1/en not_active Abandoned
- 2003-01-13 KR KR10-2004-7010748A patent/KR20040073559A/ko not_active Application Discontinuation
- 2003-01-13 BR BR0302672-8A patent/BR0302672A/pt not_active IP Right Cessation
- 2003-01-13 ES ES03729250T patent/ES2298519T3/es not_active Expired - Lifetime
- 2003-01-13 JP JP2003557559A patent/JP2005519055A/ja active Pending
- 2003-01-13 EP EP03729250A patent/EP1465614B1/en not_active Expired - Lifetime
- 2003-01-13 UA UA20040705602A patent/UA80692C2/uk unknown
- 2003-01-13 NZ NZ533737A patent/NZ533737A/en unknown
- 2003-01-13 DE DE60318387T patent/DE60318387T2/de not_active Expired - Lifetime
- 2003-01-13 IL IL16264603A patent/IL162646A0/xx unknown
- 2003-01-13 HU HU0500498A patent/HUP0500498A3/hu unknown
- 2003-01-13 PL PL371282A patent/PL215159B1/pl unknown
- 2003-01-13 AU AU2003235762A patent/AU2003235762B2/en not_active Expired - Fee Related
- 2003-01-13 WO PCT/EP2003/000236 patent/WO2003057201A2/en active IP Right Grant
- 2003-01-13 CN CNB038020629A patent/CN100377706C/zh not_active Expired - Fee Related
- 2003-01-13 YU YU75003A patent/YU75003A/sh unknown
- 2003-01-13 EE EEP200400032A patent/EE200400032A/xx unknown
- 2003-01-13 MX MXPA04006717A patent/MXPA04006717A/es active IP Right Grant
- 2003-01-13 US US10/342,044 patent/US7041699B2/en not_active Expired - Fee Related
- 2003-01-13 AT AT03729250T patent/ATE382343T1/de active
- 2003-09-05 NO NO20033950A patent/NO20033950L/no not_active Application Discontinuation
-
2004
- 2004-06-25 ZA ZA200405075A patent/ZA200405075B/en unknown
- 2004-08-03 HR HR20040704A patent/HRP20040704A2/hr not_active Application Discontinuation
- 2004-08-11 LT LT2004076A patent/LT5240B/lt unknown
- 2004-09-09 LV LVP-04-93A patent/LV13248B/en unknown
-
2006
- 2006-02-06 US US11/348,927 patent/US20060142212A1/en not_active Abandoned
- 2006-06-07 HK HK06106522A patent/HK1086489A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7041699B2 (en) | Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer | |
| Bonfili et al. | Natural polyphenols as proteasome modulators and their role as anti‐cancer compounds | |
| EP1195159B1 (en) | Therapeutic combination of ascorbate with lysine and arginine for prevention and treatment of cancer | |
| EP1463498B1 (en) | pharmaceutical COMPOSITION comprising a catechin, ascorbic acid, proline and lysine FOR THE TREATMENT OF NEOPLASTIC DISEASES | |
| Roomi et al. | Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES. 1. | |
| KR20190058346A (ko) | Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 | |
| WO2006108430A1 (en) | Nutrient composition comprising green tea polyphenols for treating osteosarcoma | |
| Roomi et al. | In vivo and In vitro effect of a nutrient mixture on human hepatocarcinoma cell line SK-HEP-1 | |
| Roomi et al. | Vitamin C in Health: Scienti� ic focus on its anti-cancer ef� icacy | |
| Roomi et al. | Inhibition of growth and expression of inflammation mediators in human leukemic cell line U-937 by a nutrient mixture | |
| Roomi et al. | In vivo and in vitro antitumor effect of nutrient synergy on human osteosarcoma cell line MNNG-HOS | |
| Ivanov et al. | Vitamin D enhances anticancer effects of EGCG and a specific micronutrient combination in breast cancer cells | |
| JP2022186086A (ja) | グルタチオン産生増強剤 | |
| WO2006108429A1 (en) | Nutrient composition for treating sarcoma and prostate cancer | |
| JP2022186085A (ja) | グルタチオン産生増強剤 | |
| Room et al. | Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES. 1 | |
| Roomi et al. | GGGGGGS GGG GG LL GGGG GGL GLLLLL GGG GLS INFLAMMarion MEDIATORS IN HUMAN LEUKEMIC CELL LINE aS000 GGG G GGaGGLLGGG GG LLLLS |